Stanley Laman Group Ltd. lifted its stake in shares of Balchem Co. (NASDAQ:BCPC) by 13.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,360 shares of the basic materials company’s stock after acquiring an additional 1,442 shares during the quarter. Stanley Laman Group Ltd.’s holdings in Balchem were worth $1,550,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. CI Investments Inc. grew its stake in shares of Balchem by 444.0% during the fourth quarter. CI Investments Inc. now owns 272 shares of the basic materials company’s stock worth $31,000 after purchasing an additional 222 shares in the last quarter. Veriti Management LLC acquired a new position in shares of Balchem during the fourth quarter worth $120,000. PBMares Wealth Management LLC acquired a new position in shares of Balchem during the first quarter worth $213,000. Bailard Inc. acquired a new position in shares of Balchem during the fourth quarter worth $217,000. Finally, Los Angeles Capital Management LLC acquired a new position in shares of Balchem during the fourth quarter worth $244,000. 85.01% of the stock is currently owned by institutional investors and hedge funds.
A number of equities analysts recently commented on BCPC shares. Zacks Investment Research downgraded shares of Balchem from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 3rd. Stephens upgraded shares of Balchem from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $100.00 to $140.00 in a research note on Monday, March 1st. Finally, HC Wainwright upped their price objective on shares of Balchem from $126.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, March 1st.
Balchem (NASDAQ:BCPC) last released its quarterly earnings data on Thursday, April 29th. The basic materials company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.80 by $0.07. Balchem had a net margin of 12.02% and a return on equity of 14.01%. The company had revenue of $185.70 million during the quarter, compared to the consensus estimate of $181.59 million. During the same quarter in the prior year, the firm posted $0.81 earnings per share. Balchem’s revenue for the quarter was up 6.4% on a year-over-year basis. On average, research analysts expect that Balchem Co. will post 2.88 earnings per share for the current year.
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
Featured Story: What is a dead cat bounce?
Want to see what other hedge funds are holding BCPC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Balchem Co. (NASDAQ:BCPC).
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.